This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC). The trial is designed to investigate VB10.16, an investigational therapeutic DNA vaccine in combination with another medicine, pembrolizumab, which is the standard of care for patients with previously untreated metastatic or resectable recurrent PD-L1 positive HNSCC. The study is divided in 2 parts: * Phase 1: Dose escalation to evaluate safety and determine the recommended phase 2 dose (RP2D) of VB10.16 * Phase 2: Randomized comparison of VB10.16 in combination with pembrolizumab versus pembrolizumab monotherapy The goal of Phase 1 is to evaluate the safety and tolerability of the combined treatment and to decide on the dose of VB10.16 to be used in the second part of the trial. The randomized Phase 2 will consist of 2 parallel arms exploring VB10.16 at the selected RP2D from the escalation phase in combination with pembrolizumab SoC (experimental arm, Arm A), versus pembrolizumab alone (control arm, Arm B).
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 8 years. 2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met. 3. The visit frequency will be every 3 weeks during the treatment period. Note: Participants on osimertinib treatment(osimertinib only arm or who have discontinued Dato-DXd while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression or IP discontinuation. Participants who are receiving osimertinib + Dato-DXd are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
About the trial
This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi ER+/HER2- potwierdzony badaniami.
- •Choroba widoczna w badaniach obrazowych lub co najmniej jedna zmiana kostna.
- •Kobiety w okresie menopauzy muszą spełniać warunki protokołu. Kobiety przed menopauzą i mężczyźni muszą stosować terapię LHRH.
- •Choroba postępująca mimo wcześniejszego leczenia (1-2 terapie hormonalne, maksymalnie 1 chemioterapia).
- •Ogólny stan zdrowia dobry (ECOG 0-1).
- •Dobre wyniki badań narządów.
✗ Disqualifies
- •Wcześniejsze leczenie lekami podobnymi do SERD, terapiami ukierunkowanymi na ER lub inhibitorami PI3K/AKI/mTOR.
- •Udział w innym badaniu w ciągu ostatnich 28 dni.
- •Przyjmowanie leków wpływających na metabolizm leków badanych w krótkim czasie przed rozpoczęciem leczenia.
- •Zaawansowane, objawowe przerzuty do narządów zagrażające życiu.
- •Aktywne przerzuty do mózgu, zapalenie opon mózgowych.
- •Ciężkie choroby serca lub problemy z pracą serca.
- •Ciąża lub karmienie piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (57)
The First Affiliated Hispital of Bengbu Medical University
Bengbu, China
Anhui Provincial Cancer Hospital
Hefei, China
The First Affiliated Hispital of Anhui Medical University
Hefei, China
Maanshan People's Hospital
Maanshan, China
Beijing Cancer Hospital
Beijing, China
The First Medical Center of PLA Ggeneral Hospital
Beijing, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Fujian Provincial Hospital
Fuzhou, China
Gansu Provincial Cancer Hospital
Lanzhou, China
Guangdong Maternal and Child Health Hospital
Guangzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Zhongshan City People's Hospital
Zhongshan, China
Guangxi Medical University Cancer hospital
Nanning, China
First Hospital Of Qinhuangdao
Qinhuangdao, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Harbin Medical University Cancer Hospital
Harbin, China
Anyang Tumor Hospital
Anyang, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, China
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Hubei Cancer Hospital
Wuhan, China
Wuhan University Zhongnan Hospital
Wuhan, China
Xiangyang Central Hospital
Xiangyang, China
The First PEOPLE'S HOSPITAL OF CHANGDE CITY
Changde, China
Hunan Cancer Hospital
Changsha, China
Xiangya Hospital of Central South University
Changsha, China
The Central Hospital of Yongzhou
Yongzhou, China
Jiangsu Cancer Hospital
Nanjing, China
Nanjing Drum Tower Hospital
Nanjing, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Xuzhou Central Hospital
Xuzhou, China
Jiangxi Cancer Hospital
Nanchang, China
Jilin Cancer Hospital
Changchun, China
The First Hospital of Jilin University
Changchun, China
The Second Hospital of Dalian Medical University
Dalian, China
The First Affiliated Hospital of JINZHOU Medical University
Jinzhou, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Hospital of China Medical University
Shenyang, China
First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
Baoji Central Hospital
Baoji, China
Binzhou Medical University Hospital
Binzhou, China
Shandong First Medical University and Shandong Academy of Medical Sciences
Jinan, China
Linyi Cancer Hospital
Linyi, China
Linyi People'S Hostipal
Linyi, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Weifang People'S Hospital
Weifang, China
Weihai Municipal Hospital
Weihai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Shanghai General Hospital
Shanghai, China
Sichuan Cancer Hospital
Chengdu, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Zhejiang Cancer Hospital
Hangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Ningbo Medical Center Lihuili Hospital
Ningbo, China
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.